uniQure N.V. (NASDAQ:QURE - Get Free Report) insider Walid Abi-Saab sold 1,466 shares of the business's stock in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $13.92, for a total value of $20,406.72. Following the completion of the sale, the insider directly owned 150,437 shares in the company, valued at approximately $2,094,083.04. This represents a 0.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
uniQure Trading Up 2.1%
Shares of NASDAQ:QURE traded up $0.29 during trading on Wednesday, hitting $14.28. The company had a trading volume of 803,752 shares, compared to its average volume of 1,961,429. The company has a debt-to-equity ratio of 1.53, a current ratio of 11.99 and a quick ratio of 11.99. uniQure N.V. has a one year low of $3.73 and a one year high of $19.18. The stock has a market cap of $782.26 million, a price-to-earnings ratio of -3.25 and a beta of 0.08. The company has a fifty day simple moving average of $14.53 and a two-hundred day simple moving average of $14.00.
uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. The firm had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. As a group, equities analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages recently weighed in on QURE. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a report on Thursday, May 29th. Chardan Capital reaffirmed a "buy" rating and set a $38.00 price objective on shares of uniQure in a research report on Friday, May 30th. Wall Street Zen lowered uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Finally, Guggenheim reiterated a "buy" rating and issued a $28.00 price target on shares of uniQure in a research note on Monday, May 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $37.82.
View Our Latest Stock Report on QURE
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the stock. Invesco Ltd. lifted its holdings in shares of uniQure by 453.2% during the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock valued at $10,836,000 after purchasing an additional 502,684 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of uniQure in the fourth quarter worth about $320,000. Assenagon Asset Management S.A. increased its holdings in shares of uniQure by 355.2% during the 1st quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock valued at $3,550,000 after purchasing an additional 261,323 shares in the last quarter. Raymond James Financial Inc. purchased a new position in uniQure in the fourth quarter valued at $1,951,000. Finally, Northern Trust Corp boosted its position in uniQure by 2.1% during the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock worth $1,688,000 after purchasing an additional 1,923 shares in the last quarter. 78.83% of the stock is owned by institutional investors.
About uniQure
(
Get Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Read More
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
